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OBJECTIVE — Toassesswhethersexdifferencesexistintheeffectivecontrolandmedication
treatment intensity of cardiovascular disease (CVD) risk factors.
RESEARCH DESIGN AND METHODS — We performed a cross-sectional analysis
including44,893patientswithtype2diabetes(51%women).Endpointsincludeduncontrolled
CVDriskfactors(LDLcholesterol130mg/dl,systolicbloodpressure[SBP]140mmHg,and
A1C 8%) and the intensity of medical management in patients with uncontrolled CVD risk
factors.Multiple-adjustedoddsratioswerecalculatedafterstratiﬁcationforthepresenceofCVD
(present in 39% of the patients).
RESULTS — Women with CVD were less likely to have SBP, LDL cholesterol, and A1C
controlled and less likely to receive intensive lipid-lowering treatment. Women without CVD
were less likely than men to have LDL cholesterol controlled with no differences in SBP or A1C
control.
CONCLUSIONS — Women with diabetes and CVD have poorer control of important mod-
iﬁable risk factors than men and receive less intensiﬁed lipid-lowering treatment.
Diabetes Care 31:1389–1391, 2008
M
ortality rates from cardiovascular
disease (CVD) have been declin-
ing during recent years in both
men and women in the U.S. and Europe
(1,2). However, in patients with diabe-
tes, a decrease has been observed only
in men (2). Furthermore, the relative
risk for fatal diabetes-associated coro-
nary heart disease is 50% higher in
women than in men (3). More adverse
cardiovascular risk proﬁles among
women with diabetes has been postu-
lated as a possible explanation, as well
as potential disparities in treatment that
favor men (3–5). A study from U.S.
managed care health plans found
poorer control of blood pressure and
LDL cholesterol in female compared
with male patients and suggested that
these ﬁndings may contribute to the sex
disparity in CVD mortality trends (6).
No study in Europe has investigated sex
disparities in the main cardiovascular
risk factors in patients with diabetes
and/or has put them into perspective
with treatment intensity.
RESEARCH DESIGN AND
METHODS— This study is a cross-
sectional trial in outpatients with type 2
diabetes using data from the DUTY regis-
try (7). Data of 44,893 patients were ob-
tained from 3,096 ofﬁce-based
physicians. End points included levels of
modiﬁable CVD risk factors, i.e., most re-
cent levels of systolic blood pressure
(SBP), LDL cholesterol, and A1C (inter-
mediateoutcomes).Theseoutcomeswere
analyzed as binary variables according to
levels considered not in control and
therefore requiring more action, as rec-
ommended by the American Diabetes As-
sociation (8). A second set of end points
was deﬁned to reﬂect the intensity of
medication management strategies of the
three outcomes for subjects with risk fac-
torvaluesatorabovethesecutpoints.For
each CVD risk factor, we calculated the
sex-speciﬁc proportion of the patients
with levels not in control who were cur-
rently receiving more intensive medica-
tion,presumablyreﬂectingagreatereffort
to manage the outcome.
Stratiﬁed by the presence or absence
of CVD, we used logistic regression mod-
elstoestimatedifferencesinthelevelsand
treatment of CVD risk factors by sex. We
estimated the probability of having CVD
riskfactorsnotundercontrolorofreceiv-
ing more intense medication for those
with poorly controlled risk factors and
modeled the risk differences between
men and women and their conﬁdence in-
tervals (CIs). The main explanatory vari-
able was patient sex. The covariates
included age, BMI, duration of diabetes,
and current smoking.
RESULTS— Subject characteristics
areshowninsupplementalTable1(avail-
able in an online appendix at http://
dx.doi.org/10.2337/dc08-0194).
Approximately 63% of the patients had
SBP 140 mmHg, 48% had LDL choles-
terol 130 mg/dl, and 24% had A1C lev-
els 8.0%. Intensive treatment with
antihypertensive agents was done in 39%
of the patients, with lipid-lowering drugs
in 32% and antihyperglycemic agents in
39%. Unadjusted risk differences were
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(online appendix, supplemental Table 2).
The upper part of Table 1 shows the
calculated odds ratios for risk factors not
under control. After multiple adjust-
ments, among patients with a CVD his-
tory, women were signiﬁcantly more
likely than men to have SBP 140
mmHg, LDL cholesterol 130 mg/dl,
andA1Clevels8.0%.Thelargestdiffer-
ences observed between men and women
were regarding LDL cholesterol control.
AmongpatientswithoutahistoryofCVD,
women were signiﬁcantly more likely
than men to have LDL cholesterol 130
mg/dl, while there was no difference in
SBP or A1C.
The lower part of Table 1 reports the
estimated probabilities of the intensity of
medication management. In adjusted
models, among those with a history of
CVD,themedicationintensitywassimilar
in men and women with respect to anti-
hypertensive and antihyperglycemic
medications, but women received signiﬁ-
cantly less lipid-lowering medications.
AmongpatientswithoutahistoryofCVD,
there were no signiﬁcant differences.
CONCLUSIONS — In this large Ger-
man population of patients with type 2
diabetes, women with a history of CVD
were more likely to have all three risk fac-
tors uncontrolled, with differences in
lipid control being the most pronounced.
Women were also less likely to receive
lipid-lowering medications. Among pa-
tients without a history of CVD, women
were more likely to have uncontrolled
LDL cholesterol. These results are of par-
ticular interest, since it has been shown
that the stronger effect of type 2 diabetes
on the risk of coronary heart disease in
women is in part explained by a greater
effect of atherogenic dyslipidemia and
blood pressure in diabetic women (9).
Our ﬁndings are consistent with previous
reports (5,10), albeit supported by a
muchlargerdatasource.Across-sectional
analysis in American patients with diabe-
tes found that women were less likely
than men to have A1C 7%, less likely to
be treated with lipid-lowering medica-
tions, and, when treated, less likely to
have LDL cholesterol 100 mg/dl (4).
Weextendtheabovedatabyshowingthat
lack of control is even more pronounced
among patients with CVD, a ﬁnding with
obvious clinical implications.
We have recently shown that among
patients with diabetes, physicians focus
more on antihyperglycemic treatment, al-
though blood pressure and lipid control
are more effective in affecting patient-
related end points (7).
A limitation of the study is its cross-
sectionaldesign.Thestrengthsincludeits
large size: 10 times higher than previ-
ouslypublishedstudiesinthisﬁeld.Ithas
been shown that a target-driven, long-
term, intensiﬁed intervention aimed at
multiple risk factors in patients with type
2 diabetes reduces the risk of cardiovas-
cular events (11). The present study
shows that diabetic women have poorer
control of important modiﬁable risk fac-
tors than diabetic men and receive less
intensiﬁed lipid-lowering therapy. More
intensive treatment of diabetic women
may improve the sex disparity in CVD
mortality.
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Table 1—Odds ratios (ORs) and 95% CIs between diabetic men and women for CVD risk factors not under control, as well as for intensity of
medicationmanagement*foreachCVDriskfactoramongpatientswithlevelsnotundercontrol(unadjustedandadjustedestimatesusingmale
sex as the referent)
With CVD (n  9,521 men
and 8,050 women)
Without CVD (n  12,417 men
and 14,905 women)
OR 95% CI P OR 95% CI P
CVD risk factors not in control (unadjusted)
SBP 140 mmHg 1.20 1.12–1.27 0.0001 1.08 1.03–1.13 0.003
LDL cholesterol 130 mg/dl 1.33 1.25–1.42 0.0001 1.21 1.15–1.28 0.0001
A1C  8% 1.04 0.97–1.11 0.32 1.01 0.95–1.07 0.82
CVD risk factors not in control (multiple adjusted)
SBP 140 mmHg 1.19 1.11–1.29 0.0001 1.0 0.95–1.06 0.99
LDL cholesterol 130 mg/dl 1.44 1.33–1.55 0.0001 1.25 1.18–1.32 0.0001
A1C 8% 1.15 1.06–1.25 0.0009 1.04 0.97–1.1 0.29
Intensity of medication management (unadjusted)
2 antihypertensive agents 1.09 1.02–1.16 0.014 1.19 1.12–1.26 0.0001
1 lipid-lowering drug 0.76 0.72–0.81 0.0001 0.99 0.93–1.04 0.62
2 oral antihyperglycemic agents or insulin 1.11 1.03–1.18 0.003 1.05 0.995–1.11 0.073
Intensity of medication management (multiple adjusted)
2 antihypertensive agents 0.998 0.92–1.08 0.97 1.01 0.95–1.08 0.71
1 lipid-lowering drug 0.85 0.79–0.91 0.0001 0.99 0.93–1.05 0.65
2 oral antihyperglycemic agents or insulin 1.04 0.95–1.13 0.40 0.96 0.9–1.03 0.25
*Outcomes analyzed as binary variables (140 vs. 140 mmHg for SBP, 130 vs. 130 mg/dl for LDL cholesterol, and 8.0 vs. 8.0% for A1C) according to
the levels considered not in control and therefore requiring more action, as recommended by the American Diabetes Association. More intense medication
management was deﬁned as the use of two or more drug classes of antihypertensive agents for hypertension, of one or more lipid-lowering agents for lipid
management, and of two or more oral agents or insulin for antihyperglycemic treatment.
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